Skip to main content

Table 2 Prevalence of Plasmodium falciparum trophozoites, anti-CSP antibodies and antimalarial drugs detected in children between two and nine years of age.

From: Antimalarial drug use in general populations of tropical Africa

ID Site

Nb of thick smears

Prevalence of trophozoites (all species)

Prevalence of Plasmodium falciparum trophozoites

Prevalence of anti-CSP antibodies

Detection of antimalarial drugs in children's urines

  

Nb of thick smears +

(%)

Nb of thick smears +

(%)

Nb of serology

Nb of serology +

(%)

CQ*

PYR†

      

CQ+‡

Prevalence

(95% CI)

PYR+§

Prevalence

(95% CI)

1

100

26 (26.0)

25 (25.0)

100

13 (13.0)

36

36.0 (26.6–46.2)

0

0.0 (0.0–3.6)

2

105

17 (16.2)

17 (16.2)

105

10 (9.5)

18

18.0 (11.0–26.9)

0

0.0 (0.0–3.6)

3

111

21 (18.9)

19 (17.1)

110

13 (11.8)

16

14.5 (8.5–22.5)

0

0.0 (0.0–3.3)

4

120

23 (19.2)

22 (18.3)

118

12 (10.2)

56

47.5 (38.2–56.9)

0

0.0 (0.0–3.1)

5

101

54 (53.5)

47 (46.5)

100

25 (25.0)

26

25.7 (17.6–35.4)

2

2.0 (0.2–7.0)

6

100

79 (79.0)

72 (72.0)

100

55 (55.0)

20

20.0 (12.7–29.2)

0

0.0 (0.0–3.6)

7

100

86 (86.0)

79 (79.0)

100

48 (48.0)

9

9.0 (4.2–16.4)

0

0.0 (0.0–3.6)

8

103

89 (86.4)

83 (80.6)

103

75 (72.8)

14

14.0 (7.9–22.4)

0

0.0 (0.0–3.6)

9

84

60 (71.4)

57 (67.9)

84

39 (46.4)

18

21.4 (13.2–31.7)

0

0.0 (0.0–4.3)

10

110

78 (70.9)

66 (60.0)

110

51 (46.4)

10

9.1 (4.4–16.1)

0

0.0 (0.0–3.3)

11

102

90 (88.2)

90 (88.2)

104

93 (89.4)

47

46.1 (36.2–56.2)

1

1.0 (0.0–5.3)

12

102

93 (91.2)

88 (86.3)

102

98 (96.1)

33

33.7 (24.4–43.9)

0

0.0 (0.0–3.7)

13

102

41 (40.2)

41 (40.2)

104

21 (20.2)

98

90.7 (83.6–95.5)

1

0.9 (0.0–5.1)

14

102

42 (41.2)

38 (37.3)

105

22 (21.0)

89

80.2(71.5–87.1)

0

0.0 (0.0–3.3)

15

100

69 (69.0)

68 (68.0)

101

24 (23.8)

60

61.9 (51.4–71.5)

0

0.0 (0.0–3.7)

16

117

100 (85.5)

99 (84.6)

115

82 (71.3)

18

16.7 (10.2–25.1)

0

0.0 (0.0–3.4)

17

102

79 (77.5)

78 (76.5)

102

88 (86.3)

18

20.0 (12.3–29.8)

1

1.1 (0.0–6.0)

18

102

98 (96.1)

98 (96.1)

105

93 (88.6)

18

18.4 (11.3–27.5)

0

0.0 (0.0–3.7)

19

101

88 (87.1)

88 (87.1)

104

78 (75.0)

31

31.3 (22.4–41.4)

0

0.0 (0.0–3.7)

20

104

55 (52.9)

53 (51.0)

104

30 (28.8)

66

68.8 (58.5–77.8)

1

1.0 (0.0–5.7)

21

101

65 (64.4)

55 (54.5)

99

23 (23.2)

49

51.0 (40.6–61.4)

20

20.8 (13.2–30.3)

22

103

83 (80.6)

80 (77.7)

66

25 (37.9)

89

89.0 (81.2–94.4)

0

0.0 (0.0–3.6)

23

101

79 (78.2)

72 (71.3

99

46 (46.5)

35

34.7 (25.5–44.8)

1

1.0 (0.0–5.4)

24

101

65 (64.4)

59 (58.4)

99

32 (32.3)

68

67.3 (57.3–76.3)

0

0.0 (0.0–3.6)

25

100

52 (52.0)

41 (41.0)

86

16 (18.6)

91

87.5 (79.6–93.2)

0

0.0 (0.0–3.5)

26

101

86 (85.1)

74 (73.3)

102

29 (28.4)

56

55.4 (45.2–65.3)

0

0.0 (0.0–3.6)

27

99

83 (83.8)

81 (81.8)

48

8 (16.7)

28

27.2 (18.9–36.8)

0

0.0 (0.0–3.5)

28

104

87 (83.7)

84 (80.8)

95

21 (22.1)

42

39.6 (30.3–49.6)

0

0.0 (0.0–3.4)

29

103

81 (78.6)

76 (73.8)

103

22 (21.4)

25

24.3 (16.4–33.7)

0

0.0 (0.0–3.5)

30

107

91 (85.0)

86 (80.4)

107

34 (31.8)

78

72.9 (63.4–81.0)

2

1.9 (0.2–6.6)

Total

3088

2060 (66.7)

1936 (62.7)

2980

1226 (41.1)

1262

41.3 (39.6–43.0)

29

1 (0.6–1.4)

  1. Nb: number; %, percent, *CQ: Chloroquine, † PYR: Pyrimethamine, ‡ CQ+ = number of samples with chloroquine in urine, § PYR+: number of samples with pyrimethamine in urine, Prevalence: expressed in percent.